XRCC1 and breast carcinoma: Furthermore, inhibitors targeting single-stranded DNA binding protein Replication protein A (RPA) and X-ray repair cross-complementing 1 (XRCC1) have also shown the potential to increase the sensitivity of various tumors, including breast cancer, liver cancer, and head and neck squamous cell carcinoma, to radiotherapy (76).